Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET-TAIL: Sotrovimab IM vs IV in COVID-19
NCT04913675Phase 3Terminated
- Sponsor
- Vir Biotechnology
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Vir Biotechnology. Started Jun 2021; status: terminated.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04913675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913675.